We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

EUS-guided Fine Needle Aspiration (EUS-FNA) Versus EUS-guided Fine Needle Biopsy (EUS-FNB) for Diagnosis of Subepithelial Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02943837
Recruitment Status : Withdrawn (Funding issues)
First Posted : October 25, 2016
Last Update Posted : January 13, 2021
Information provided by (Responsible Party):
Kee Don Choi, Asan Medical Center

Brief Summary:

Background: Preoperative pathologic diagnosis of subepithelial tumor (SET) can improve clinical decision making. Although EUS-guided fine needle aspiration (FNA) is currently considered the standard method for sampling SET, its diagnostic yield is generally suboptimal. EUS-guided fine needle biopsy (FNB) of SET is safe and feasible with adequate histology obtained.

Objective: To compare the diagnostic accuracy of EUS-FNA and EUS-FNB.

Condition or disease Intervention/treatment Phase
Gastrointestinal Subepithelial Tumors Procedure: Device: 22G FNA needle Procedure: Device: 20G FNB needle Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Actual Study Start Date : October 1, 2016
Actual Primary Completion Date : December 1, 2016
Actual Study Completion Date : December 1, 2016

Arm Intervention/treatment
Active Comparator: EUS-FNA
Device: 22G FNA needle
Procedure: Device: 22G FNA needle
Experimental: EUS-FNB
Device: 20G FNB needle
Procedure: Device: 20G FNB needle

Primary Outcome Measures :
  1. Diagnostic accuracy (proportion of correctly classified subjects (ture positive + true negative) among all subjects ) , compared to the gold standard diagnosis [ Time Frame: 12 months ]

    Gold standard diagnosis is defined as;

    1. in operated patients; histological assessment of the surgical resection specimen
    2. in non-operated patients; based on the conclusions of the diagnostic work-up (combined outcomes of FNA and FNB samples and imaging studies)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Esophageal, gastric, or duodenal SET over 2 cm
  • Hypoechoic lesion including 4th layer on EUS

Exclusion Criteria:

  • SET with characteristic findings such as lipoma, vessels, or ectopic pancreas
  • bleeding or rupture of SET
  • platelet count <50,000 or prothrombin time INR > 1.3
Layout table for additonal information
Responsible Party: Kee Don Choi, Associate professor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT02943837    
Other Study ID Numbers: AMCSMT 001
First Posted: October 25, 2016    Key Record Dates
Last Update Posted: January 13, 2021
Last Verified: January 2021